ω-3 fatty acids suppress inflammatory cytokine production by macrophages and hepatocytes

J Pediatr Surg. 2010 Dec;45(12):2412-8. doi: 10.1016/j.jpedsurg.2010.08.044.

Abstract

Objective: Long-term total parenteral nutrition (TPN) in children is often complicated by parental nutrition-associated liver disease and may even lead to liver failure. Recently, the addition of ω-3 fatty acids to TPN has been shown to reduce the risk of parental nutrition-associated liver disease. The purpose of this study was to explore the anti-inflammatory effects of ω-3 fatty acids (eicosapentaenoic acid [EPA]) to demonstrate the protection of the liver against hepatic steatosis and damage.

Materials and methods: Lipopolysaccharide (LPS) and prostaglandin E(2) (PGE(2)) were used to stimulate human macrophages and hepatocytes (THLE-3) to induce in vitro inflammatory condition. The cells were then incubated with either ω-3 (EPA) or ω-6 (arachidonic acid) fatty acids. Supernatants were collected at different time points for the measurement of tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), and interleukin 10 (IL-10) using enzyme-linked immunosorbent assay. Furthermore, pretreated macrophages by LPS stimulation and after incubation with EPA were added to prestimulated hepatocytes for the subsequent measurement of cytokine response.

Results: Eicosapentaenoic acid effectively reduced LPS-induced or PGE(2)-induced TNF-α and IL-6 expression, and increased IL-10 expression significantly when compared with arachidonic acid. Furthermore, supernatant collected after co-culturing EPA with macrophages also suppressed the levels of TNF-α and IL-6 in hepatocytes. This would suggest that EPA not only had an anti-inflammatory effect on macrophages and hepatocytes directly, it could indirectly reduce hepatocyte inflammation through activated macrophages.

Conclusions: The addition of ω-3 fatty acids in TPN suppresses the inflammatory response via direct and indirect routes. The findings may help explain the clinical benefits of EPA in pediatric patients receiving long-term TPN.

Publication types

  • Comparative Study

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Arachidonic Acid / pharmacology
  • Cell Line / drug effects
  • Cell Line / metabolism
  • Cells, Cultured / drug effects
  • Cells, Cultured / metabolism
  • Coculture Techniques
  • Depression, Chemical
  • Dinoprostone / pharmacology
  • Drug Evaluation, Preclinical
  • Eicosapentaenoic Acid / pharmacology*
  • Gene Expression Regulation / drug effects
  • Hepatocytes / drug effects*
  • Hepatocytes / metabolism
  • Humans
  • Interleukin-10 / biosynthesis*
  • Interleukin-10 / genetics
  • Interleukin-6 / biosynthesis*
  • Interleukin-6 / genetics
  • Lipopolysaccharides / pharmacology
  • Macrophages / drug effects*
  • Macrophages / metabolism
  • Parenteral Nutrition, Total
  • Tumor Necrosis Factor-alpha / biosynthesis*
  • Tumor Necrosis Factor-alpha / genetics

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • IL10 protein, human
  • IL6 protein, human
  • Interleukin-6
  • Lipopolysaccharides
  • Tumor Necrosis Factor-alpha
  • Interleukin-10
  • Arachidonic Acid
  • Eicosapentaenoic Acid
  • Dinoprostone